MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
51.37
-1.31
-2.49%
After Hours: 51.37 0 0.00% 18:58 12/05 EST
OPEN
52.15
PREV CLOSE
52.68
HIGH
52.74
LOW
50.86
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
90.32
52 WEEK LOW
41.50
MARKET CAP
2.76B
P/E (TTM)
-27.8988
1D
5D
1M
3M
1Y
5Y
1D
*Soleno Therapeutics Announces the Passing of Bd Member William G. Harris
Dow Jones · 3d ago
Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Dow Jones · 3d ago
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Barchart · 4d ago
Aardvark Therapeutics initiated with a Strong Buy at Raymond James
TipRanks · 4d ago
Weekly Report: what happened at SLNO last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at SLNO last week (1117-1121)?
Weekly Report · 11/24 10:38
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett
Reuters · 11/19 23:49
Soleno Therapeutics Price Target Announced at $75.00/Share by Wolfe Research
Dow Jones · 11/18 16:55
More
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.